You have a valid point on past studies on 2mg. The purpose of the P3 study design was to determine lowest effective dose hence the stage gate approach. 2mg x2 studies set the benchmark (threshold) for both PAR and FDA. Ironically It actually mitigates our risk BUT also translates into extra cost and time.
Where we at?, page-375
-
- There are more pages in this discussion • 332 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $104.9M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 29.5¢ | $89.62K | 294.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20607 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 16773 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |